German biotech firm CureVac filed a patent‑infringement lawsuit against Moderna in a Delaware federal court on April 24 2026, alleging that Moderna’s COVID‑19 vaccine Spikevax infringes on eight of CureVac’s U.S. patents covering messenger‑RNA (mRNA) stabilization and delivery technologies that the company says are core to its vaccine platform.
The patents at issue protect methods for chemically stabilizing mRNA strands and for delivering them into cells, technologies that are essential for producing effective mRNA vaccines. CureVac is seeking royalties from Spikevax sales as damages, a claim that could translate into significant revenue for the company if the court rules in its favor.
The lawsuit is part of a broader wave of patent disputes in the mRNA vaccine sector. BioNTech, which acquired CureVac last year, filed a separate U.S. patent lawsuit against Moderna in February 2026 over its next‑generation mNEXSPIKE shot, and Moderna has previously sued Pfizer and BioNTech in 2022 over Comirnaty. Other players such as GSK, Bayer, and Alnylam have also pursued litigation to secure shares of the COVID‑19 vaccine market.
The filing could lead to substantial litigation costs and potential damages for Moderna, while giving CureVac a chance to enforce its intellectual‑property rights and negotiate licensing or settlement terms. Moderna has acknowledged the lawsuit and stated it will defend itself, but the outcome could influence the company’s use of similar mRNA constructs and its broader strategy for vaccine development.
The case underscores the strategic importance of mRNA stabilization and delivery technologies in the competitive landscape of COVID‑19 vaccines and highlights how intellectual‑property battles can shape the trajectory of companies that rely on this emerging platform.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.